Concepedia

James Xu

JX

Statistics

Publications

3

Citations

500

H-Index

3

Active since

2017

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

James Xu is an author at United States Food and Drug Administration specializing in medicine, pharmacotherapy, and health sciences.

ORCID

Top concepts

Publications per year

2017–2021

3

Publications

3

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

V. Ellen Maher, Laura L. Fernandes, Chana Weinstock et al. · Journal of Clinical Oncology · 2019 · 336 citations

FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis

James Xu, V. Ellen Maher, Lijun Zhang et al. · The Oncologist · 2017 · 149 citations · Full text

Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials

Jaleh Fallah, Lijun Zhang, Anup Amatya et al. · The Lancet Oncology · 2021 · 15 citations

, , +9

1–3 of 3